Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 2:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 2,386 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Progressive Clear all
Completed No phase listed Observational

Imaging Biomarkers of Tissue Microstructure and Vasculature as Predictors of Glioblastoma Multiforme

NCT01604590
View directory record Official record
Conditions
Glioblastoma
Interventions
Magnetic Resonance Imaging (MRI)
Radiation
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 80 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 13, 2015 · Synced Oct 25, 2026, 2:29 PM EDT
Recruiting Phase 1 Interventional

A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma

NCT07464925
View directory record Official record
Conditions
Glioblastoma Multiforme of Brain, Glioma, Glioblastoma
Interventions
GLIX1
Drug
Lead sponsor
Tetragon Biosciences Ltd
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Tampa, Florida • Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 25, 2026, 2:29 PM EDT
Completed Phase 2 Interventional Results available

Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone Lymphoma

NCT03846427
View directory record Official record
Conditions
Marginal Zone Lymphoma, MZL
Interventions
Zanubrutinib
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Westbury, New York • Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 26, 2024 · Synced Oct 25, 2026, 2:29 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Idebenone for Primary Progressive Multiple Sclerosis

NCT01854359
View directory record Official record
Conditions
Multiple Sclerosis, Primary Progressive Multiple Sclerosis
Interventions
Idebenone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Oct 25, 2026, 2:29 PM EDT
Completed Phase 3 Interventional Results available

Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)

NCT03976323
View directory record Official record
Conditions
Carcinoma, Nonsquamous Non-small-cell Lung
Interventions
Pembrolizumab, Pemetrexed, Carboplatin, Cisplatin, Olaparib
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,003 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
20
States / cities
Birmingham, Alabama • Muscle Shoals, Alabama • Burbank, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 25, 2026, 2:29 PM EDT
Completed No phase listed Observational

Effect of Interferon Beta-1a (Avonex®) on Changes of Non-conventional MRI Measures in Patients With MS

NCT00463710
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Avonex® monotherapy (6.0 MIU administered i.m. each week)
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Dec 28, 2020 · Synced Oct 25, 2026, 2:29 PM EDT
Completed Phase 2 Interventional Results available

Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma

NCT00153920
View directory record Official record
Conditions
Multiple Myeloma
Interventions
bortezomib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
6
States / cities
Atlanta, Georgia • Boston, Massachusetts • Buffalo, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2019 · Synced Oct 25, 2026, 2:29 PM EDT
Completed No phase listed Observational

Methemoglobinemia in Young Patients With Hematologic Cancer or Aplastic Anemia Treated With Dapsone

NCT00993694
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Methemoglobinemia, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Nonmalignant Neoplasm
Interventions
chemotherapy, dapsone, medical chart review, assessment of therapy complications
Drug · Other · Procedure
Lead sponsor
Vanderbilt University
Other
Eligibility
Up to 18 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
2
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Oct 25, 2026, 2:29 PM EDT
Recruiting Phase 3 Interventional

A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis

NCT07299019
View directory record Official record
Conditions
Secondary Progressive Multiple Sclerosis
Interventions
Orelabrutinib, Placebo
Drug
Lead sponsor
Zenas BioPharma (USA), LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
990 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
26
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Fullerton, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 25, 2026, 2:29 PM EDT
Completed Phase 1Phase 2 Interventional

Strength Training and Stroke

NCT00629005
View directory record Official record
Conditions
Stroke
Interventions
Constraint-Induced Movement Therapy + strength training, Constraint-Induced Movement Therapy + range of motion
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 29, 2013 · Synced Oct 25, 2026, 2:29 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis

NCT04676529
View directory record Official record
Conditions
Myelofibrosis, Primary Myelofibrosis (PMF), Post- Essential Thrombocythemia Myelofibrosis, Post Polycythemia Vera Myelofibrosis
Interventions
PXS-5505
Drug
Lead sponsor
Syntara
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
3
States / cities
Birmingham, Alabama • Winston-Salem, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 25, 2026, 2:29 PM EDT
Recruiting Phase 1 Interventional

A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders

NCT06680037
View directory record Official record
Conditions
B-cell Mediated Autoimmune Disorders
Interventions
Azercabtagene zapreleucel (azer-cel)
Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
8
States / cities
La Jolla, California • Ann Arbor, Michigan • Omaha, Nebraska + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 25, 2026, 2:29 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

4-Repeat Tauopathy Neuroimaging Initiative - Cycle 2

NCT02966145
View directory record Official record
Conditions
Corticobasal Degeneration (CBD), Corticobasal Syndrome (CBS), Cortical-basal Ganglionic Degeneration (CBGD), Progressive Supranuclear Palsy (PSP), Nonfluent Variant Primary Progressive Aphasia (nfvPPA), Oligosymptomatic/Variant Progressive Supranuclear Palsy (o/vPSP)
Interventions
Observational Study
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
40 Years to 80 Years
Enrollment
293 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2024
U.S. locations
7
States / cities
San Diego, California • San Francisco, California • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2025 · Synced Oct 25, 2026, 2:29 PM EDT
Completed Phase 2 Interventional

Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment

NCT00066248
View directory record Official record
Conditions
Brain Tumor, Central Nervous System Tumors, Cachexia, Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
cyproheptadine hydrochloride, megestrol acetate
Drug
Lead sponsor
University of South Florida
Other
Eligibility
2 Years to 20 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
40
States / cities
Oakland, California • Washington D.C., District of Columbia • Gainesville, Florida + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2014 · Synced Oct 25, 2026, 2:29 PM EDT
Completed Not applicable Interventional

Programming Aquatic Therapy for POTS

NCT07182578
View directory record Official record
Conditions
Postural Orthostatic Tachycardia Syndrome (POTS)
Interventions
Aquatic Occupational Therapy
Other
Lead sponsor
California State University, Dominguez Hills
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 25, 2026, 2:29 PM EDT
Completed No phase listed Observational

Enhanced Recovery After Surgery in Colorectal Surgery: A Large-Scale Quality Improvement Project

NCT03189550
View directory record Official record
Conditions
Colorectal Surgery, Quality Improvement, Perioperative Care, ERAS
Interventions
ERAS perioperative care, Standard perioperative care, Noninvasive hemodynamic monitoring
Procedure
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
664 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 21, 2019 · Synced Oct 25, 2026, 2:29 PM EDT
Completed Phase 1 Interventional

Ixabepilone and Sunitinib Malate in Treating Patients With Progressive Advanced Solid Tumors

NCT00884676
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Ixabepilone, Sunitinib
Drug
Lead sponsor
Jaime Merchan
Other
Eligibility
18 Years to 120 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 9, 2015 · Synced Oct 25, 2026, 2:29 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Postural Instability in Progressive Supranuclear Palsy

NCT01563276
View directory record Official record
Conditions
Progressive Supranuclear Palsy, Parkinson's Disease
Interventions
Not listed
Lead sponsor
Oregon Health and Science University
Other
Eligibility
40 Years to 85 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 13, 2019 · Synced Oct 25, 2026, 2:29 PM EDT
Active, not recruiting Phase 2 Interventional

Efficacy of Cognitive Behavioral Therapy for Insomnia to Treat Insomnia Symptoms in Individuals With Multiple Sclerosis

NCT06428006
View directory record Official record
Conditions
Multiple Sclerosis, Insomnia
Interventions
Cognitive behavioral therapy for insomnia, Sleep and lifestyle education
Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 25, 2026, 2:29 PM EDT
Suspended Phase 1 Interventional

A Study of SGT-53 in Children With Refractory or Recurrent Solid Tumors

NCT02354547
View directory record Official record
Conditions
Neoplasm
Interventions
SGT-53, Topotecan, Cyclophosphamide
Genetic · Drug
Lead sponsor
SynerGene Therapeutics, Inc.
Industry
Eligibility
12 Months to 21 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 25, 2026, 2:29 PM EDT
Completed No phase listed Observational

S9007, Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers

NCT00996047
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
cytogenetic analysis, fluorescence in situ hybridization
Genetic
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Not listed
Enrollment
3,341 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 2012
U.S. locations
280
States / cities
Mobile, Alabama • Anchorage, Alaska • Tucson, Arizona + 182 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 25, 2026, 2:29 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease

NCT04419025
View directory record Official record
Conditions
COVID, Sars-CoV2, SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere, Oxidative Stress
Interventions
N-acetylcysteine
Drug
Lead sponsor
Cambridge Health Alliance
Other
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
4
States / cities
Cambridge, Massachusetts • Everett, Massachusetts • Somerville, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 28, 2021 · Synced Oct 25, 2026, 2:29 PM EDT
Completed Phase 1 Interventional

A Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis

NCT02601885
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
ABT-555, Placebo
Drug · Other
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
8
States / cities
Orlando, Florida • Lenexa, Kansas • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated May 17, 2018 · Synced Oct 25, 2026, 2:29 PM EDT
Completed Phase 2 Interventional Results available

Monoclonal Antibody 3F8 and Sargramostim in Treating Patients With Neuroblastoma

NCT00072358
View directory record Official record
Conditions
Neuroblastoma
Interventions
anti-GD2 murine IgG3 monoclonal antibody 3F8
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 16, 2022 · Synced Oct 25, 2026, 2:29 PM EDT